Effects of a single 50% extra dose of methadone on heroin craving and mood in lower-versus higher-dose methadone patients

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 450-454

  Strasser, Johannes ^a   Wiesbeck, Gerhard A ^a   Meier, Natalie ^a   Stohler, Rudolf ^b   Dürsteler Macfarland, Kenneth M ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

craving; extra dose; maintenance treatment; methadone; mood; opioid dependence

Indexed keywords

METHADONE; NARCOTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEROIN DEPENDENCE; HUMAN; LOW DRUG DOSE; MALE; MOOD; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; VISUAL ANALOG SCALE; AFFECT; CROSSOVER PROCEDURE; DOSE RESPONSE; PSYCHOLOGY;

ADULT; AFFECT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; NARCOTICS;

EID: 77955173083     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e6df49     Document Type: Article

References (40)

1. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221-226.
2. Trafton JA, Minkel J, Humphreys K. Determining effective methadone doses for individual opioid-dependent patients. PLoS Med. 2006;3:e80.
3. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome. New York: Springer; 1991.
4. Dickinson GL, Rostami-Hodjegan A, Lagundoye O, et al. A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. J Clin Pharm Ther. 2006;31:477-484.
5. Gerra G, Ferri M, Polidori E, et al. Long-term methadone maintenance effectiveness: psychosocial and pharmacological variables. J Subst Abuse Treat. 2003;25:1-8.
6. Faggiano F, Vigna-Taglianti F, Versino E, et al. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev. 2003;3:CD002208. Review.
7. Dyer KR, White JM. Patterns of symptom complaints in methadone maintenance patients. Addiction. 1997;92:1445-1455.
8. Parrino M. State Methadone Treatment Guidelines. Rockville, MD: US Department of Health and Human Services, Public Health Service Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment; 1993.
9. McCaul ME, Stitzer ML, Bigelow GE, et al. Intravenous hydromorphone: effects in opiate-free and methadone maintenance subjects. NIDA Res Monogr. 1983;43:238-244.
10. Preston KL, Bigelow GE, Bickel W, et al. Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. J Pharmacol Exp Ther. 1987;243:1002-1009.
11. Volavka J, Verebey K, Resnick R, et al. Methadone dose, plasma level, and cross-tolerance to heroin in man. J Nerv Ment Dis. 1978;166:104-109.
12. Jones BE, Prada JA. Drug-seeking behavior during methadone maintenance. Psychopharmacologia. 1975;41:7-10.
13. Martin WR, Jasinski DR, Haertzen CA, et al. Methadone: a reevaluation. Arch Gen Psychiatry. 1973;28:286-295.
14. Zaks A, Fink M, Freedman AM. Duration of methadone induced cross-tolerance to heroin. Br J Addict Alcohol Other Drugs. 1971;66:205-208.
15. Hiltunen AJ, Beck O, Hjemdahl P, et al. Rated well-being in relation to plasma concentrations of L-and D-methadone in dissatisfied patients on methadone maintenance treatment. Psychopharmacology. 1999;143:385-393.
16. Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher-dose methadone. J Psychoactive Drugs. 1999;31:95-102.
17. Goldsmith DS, Hunt DE, Lipton DS, et al. Methadone folklore: beliefs about side effects and their impact on treatment. Hum Organ. 1984;43:330-340.
18. Best D, Harris J, Gossop M, et al. Use of prescription methadone and other illicit drugs during methadone maintenance treatment. Drug Alcohol Rev. 2000;19:9-16.
19. Fountain J, Strang J, Gossop M, et al. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction. 2000;95:393-406.
20. Gossop M, Strang J, Connell PH. The response of out-patient opiate addicts to the provision of a temporary increase in their prescribed drugs. Br J Psychiatry. 1982;141:338-343.
21. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry. 2000;57:395-404.
22. Stitzer ML, Bickel WK, Bigelow GE, et al. Effect of methadone dose contingencies on urinalysis test results of polydrug-abusing methadone-maintenance patients. Drug Alcohol Depend. 1986;18:341-348.
23. Greenwald MK. Heroin craving and drug use in opioid-maintained volunteers: effects of methadone dose variations. Exp Clin Psychopharmacol. 2002;10:39-46.
24. Curran HV, Bolton J, Wanigaratne S, et al. Additional methadone increases craving for heroin: a double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. Addiction. 1999;94:665-674.
25. Higgins ST, Stitzer ML, Bigelow GE, et al. Contingent methadone delivery: effects on illicit-opiate use. Drug Alcohol Depend. 1986;17:311-322.
26. Rounsaville BJ, Petry NM, Carroll KM. Single versus multiple drug focus in substance abuse clinical trials research. Drug Alcohol Depend. 2003;70:117-125.
27. Dyer KR, White JM, Foster DJ, et al. The relationship between mood state and plasma methadone concentration in maintenance patients. J Clin Psychopharmacol. 2001;21:78-84.
28. Gsellhofer B, Küfner H, Vogt M, et al. European Addiction Severity Index: Manual für Training und Durchführung. Baltmannsweiler, Germany: Schneider Verlag Hohengehren GmbH; 1999.
29. Heinz AJ, Epstein DH, Schroeder JR, et al. Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat. 2006;31:355-364.
30. Zerssen von D. Die Befindlichkeits-Skala. Weinheim, Germany: Beltz Test GmbH; 1976.
31. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav. 1990;15:487-490.
32. Stitzer ML, Bigelow GE, Liebson IA. Single-day methadone dose alteration: detectability and symptoms. Clin Pharmacol Ther. 1984;36:244-250.
33. Robles E, Gilmore-Thomas KK, Miller FB, et al. Sensitivity to acute methadone dose changes in maintenance patients. J Subst Abuse Treat. 2002;23:409-413.
34. O'Brien CP, Childress AR, McLellan AT, et al. Classical conditioning in drug-dependent humans. Ann N Y Acad Sci. 1992;654:400-415.
35. Bell J, Bowron P, Lewis J, et al. Serum levels of methadone in maintenance clients who persist in illicit drug use. Br J Addict. 1990;85:1599-1602.
36. Sweeney CT, Fant RV, Fagerstrom KO, et al. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs. 2001;15:453-467.
37. Preston KL, Griffiths RR, Stitzer ML, et al. Diazepam and methadone interactions in methadone maintenance. Clin Pharmacol Ther. 1984;36:534-541.
38. Krantz MJ, Kutinsky IB, Robertson AD, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy. 2003;23:802-805.
39. Langleben DD, Ruparel K, Elman I, et al. Acute effect of methadone maintenance dose on brain fMRI response to heroin-related cues. Am J Psychiatry. 2008;165:390-394.
40. Walter M, Wiesbeck GA, Bloch N, et al. Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: a pilot study. Eur Neuropsychopharmacol. 2008;18:390-393.